Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Non-Current Deffered Revenue (2019 - 2021)

Harmony Biosciences Holdings' Non-Current Deffered Revenue history spans 3 years, with the latest figure at $192000.0 for Q1 2021.

  • On a quarterly basis, Non-Current Deffered Revenue changed N/A to $192000.0 in Q1 2021 year-over-year; TTM through Mar 2021 was $192000.0, a N/A change, with the full-year FY2020 number at $212000.0, down 26.13% from a year prior.
  • Non-Current Deffered Revenue hit $192000.0 in Q1 2021 for Harmony Biosciences Holdings, down from $212000.0 in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for HRMY hit a ceiling of $305000.0 in Q3 2020 and a floor of $192000.0 in Q1 2021.
  • Historically, Non-Current Deffered Revenue has averaged $249000.0 across 3 years, with a median of $249500.0 in 2019.
  • The widest YoY moves for Non-Current Deffered Revenue: up 26.13% in 2020, down 26.13% in 2020.
  • Tracing HRMY's Non-Current Deffered Revenue over 3 years: stood at $287000.0 in 2019, then decreased by 26.13% to $212000.0 in 2020, then decreased by 9.43% to $192000.0 in 2021.
  • Business Quant data shows Non-Current Deffered Revenue for HRMY at $192000.0 in Q1 2021, $212000.0 in Q4 2020, and $305000.0 in Q3 2020.